Despite Positive Data, Can Genocea Build A Market?
This article was originally published in Scrip
Executive Summary
Genocea Biosciences is one step closer to moving its lead candidate into Phase III, but despite positive results, there may not be a strong market for the drug. Unlike the buzz around immunotherapies in oncology, Genocea has not been able to harness that excitement for its non-cancer immunotherapy.
You may also be interested in...
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Update: Ziopharm Study Death Not Due To Drug
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.